Spray Dried Vaccine Platform


Developing innovative dry powder vaccine formulations to increase affordability, ease of use, and effectiveness of vaccines against respiratory infectious diseases

A revolutionary approach to make vaccines realistically available for everyone, everywhere

SIGN UP FOR OUR NEWSLETTER FOR THE LATEST INNOVATIVE ADVANCEMENTS

AAHI's Spray Dried Vaccine Platform Priorities

Developing traditional (subunit protein) and RNA vaccines in an aerosolized dry powder to be delivered directly to the nose or the lungs

STABILITY

BETTER PROTECTION

GREATER UPTAKE

High-Volume, Rapid Production

A Scalable Manufacturing Process

Spray dried vaccine manufacturing is a continuous manufacturing process that enables high-volume, rapid production at commercial scale.

Currently available dried vaccine technology, freeze-dried, requires batch production - a multip-step process to manufacture drug product in smaler quantities, or batches. 

Continuous, mass vaccine production is suitable for large-scale production to meet global demand of protection against disease. 

AAHI has in-house spray dried vaccine manufacturing capabilities and looks forward to scaling the process for cGMP production. 

Learn more about AAHI's manufacturing experience.

Meet Our Team

Senior VP, Formulations

Christopher Fox, PhD

Leads AAHI's vaccine adjuvant formulation platform development and optimization.

CONSultant

Reinhard Vehring, PhD

Leads the spray dried vaccine development with extensive particle engineering, design, and analysis experience.

Principal Scientist

Alana Gerhardt, PhD

Leads the Product Development and Characterization team at AAHI.

Scientist II

Wynton McClary, PhD

Drives efforts to improve the long-term storage stability of AAHI's RNA vaccine platform

scientist i

John Chen, PhD

Supports the spray dried vaccine development with extensive experience in inhaled and intranasal formulations.